Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Blood (2025) 146 (Supplement 1): 2128.

https://doi.org/10.1182/blood-2025-2128

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Toby Eyre, Leyla Mohseninejad, Lianne Barnieh, Kaijun Wang, Keri Yang, Rhys Williams

Blood (2025) 146 (Supplement 1): 5365.

https://doi.org/10.1182/blood-2025-5365

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

Michael Wang, Yuqin Song, Olivier Hermine, Yuerong Shuang, Wojciech Jurczak, João Samuel de Holanda Farias, Carolina Mahuad, Muhit Ozcan, Ron D. Jachimowicz, Tianlei Chen, Elena Ivanova, Xiaotong Li, Gabriel Man, Priscille Bourquelot, Remus Vezan, Toby Eyre

Blood (2025) 146 (Supplement 1): 663.

https://doi.org/10.1182/blood-2025-663

Published: 2025

Journal Articles

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Blood (2025) 146 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2025-3885

Published: 2025

Journal Articles

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

Blood (2025) 146 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2025-1827

Published: 2025

Journal Articles

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Lexy Sorrell, Toby Eyre, Mats Jerkeman, Simon Rule, Dave Wright, Cathy Burton, Mark Bishton, Andrew Davies, Christopher McNamara, Kristina Sonnevi, Jon Riise, Christian Poulsen, Ingemar Lagerlöf, Ingrid Glimelius, Karin Wader, David Lewis

Blood (2025) 146 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2025-1822

Published: 2025

Journal Articles

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Blood (2025) 146 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2025-1804

Published: 2025

Journal Articles

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Blood (2025) 146 (Supplement 1): 66.

https://doi.org/10.1182/blood-2025-66

Published: 2025

Journal Articles

Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions

Carmine Deluca, Toby Eyre, Christine Ryan, Kami Maddocks, Pier Luigi Zinzani, Michael Beyer, Ben Johnson, Abigail Brugger, Jessica Massey, Andrea Corti

Blood (2025) 146 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2025-2869

Published: 2025

Journal Articles

Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials

Toby Eyre, Lisa M. Hess, Ehsan Masoudi, Min-Hua Jen, Sarang Abhyankar, Peita Graham-Clarke, Naleen Raj Bhandari, Peter Maguire, Katherine Winfree, Marsha Tracey, Kaisa-Leena Taipale, Matthew S Davids

Blood (2025) 146 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2025-5684

Published: 2025

Journal Articles

Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank

Georgina Naylor, Sarah Mant, Asha Omar, Lexy Sorrell, Nicola Crosbie, Peninsula Clinical Trials Unit, Kristian Bowles, Safia Dawi, Christopher McNamara, Melanie Oates, Mark Bishton, Toby Eyre, Andrew Pettitt, Simon Rule, David Lewis

Blood (2025) 146 (Supplement 1): 5376.

https://doi.org/10.1182/blood-2025-5376

Published: 2025

Journal Articles

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Toby Eyre, Matthew S Davids, Jeff Sharman, Paul Barr, Catherine Coombs, Wojciech Jurczak, Koji Izutsu, Meghan Thompson, William Wierda, Ying (denise) Wang, Marisa Hill, Donald Tsai, Ching Ching Leow, Sarang Abhyankar, Paolo Ghia, Jennifer Woyach

Blood (2025) 146 (Supplement 1): 5670.

https://doi.org/10.1182/blood-2025-5670

Published: 2025

Journal Articles

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Krish Patel, Jennifer Crombie, Tycel Phillips, Michael Dickinson, Toby Eyre, Chan Cheah, Stephen Schuster, Nirav Shah, Georg Lenz, Laurie Sehn, Donald Tsai, Erica Johnston, Sonya Chapman, Hongmei Han, Minna Balbas, Ching Ching Leow, Gilles Salles

Blood (2025) 146 (Supplement 1): 5524.

https://doi.org/10.1182/blood-2025-5524

Published: 2025

Journal Articles

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia

Toby Eyre, Claire J. Schwab, Ross Kinstrie, Ann Keen McGuire, Jen Strefford, Andrew Peniket, Adam Mead, Tim Littlewood, Tessa L. Holyoake, Mhairi Copland, Anthony V. Moorman, Christine J. Harrison, Paresh Vyas

Blood (2012) 120 (22): 4441–4443.

https://doi.org/10.1182/blood-2012-09-456517

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions

Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials

Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only